BioSpace News Archive

Pharm Country

BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

BioRestorative Therapies, Inc . today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program.

March 2, 2023
·
3 min read
Biotech Beach

PreludeDx™ Presents New Data at the 40th Annual Miami Breast Cancer Conference Identifying Which Patients with DCIS May Be Undertreated Based on Clinicopathologic Factors Alone

Prelude Corporation today announced it will be presenting data at the 40th Annual Miami Breast Cancer Conference (MBCC), being held on March 2 – 5, 2023 at the Fontainebleau Miami Beach.

March 2, 2023
·
5 min read
Drug Development

Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Galectin Therapeutics, Inc. announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH).

March 2, 2023
·
7 min read
Biotech Beach

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results Management to host conference call and webcast on March 9th at 5:00 pm EST / 2:00 pm PST

aTyr Pharma, Inc. today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023.

March 2, 2023
·
1 min read
Drug Development

BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease

BioVie Inc. today announced that its NM101 trial evaluating NE3107 in the treatment of patients with Alzheimer’s Disease, has achieved its revised enrollment target of 400 patients.

March 2, 2023
·
6 min read
Vaxxinity to Present at Upcoming March Scientific and Medical ConferencesVaxxinity to present new preclinical data on anti-tau Alzheimer’s vaccine candidate VXX-301 at AD/PD International Conference

Vaxxinity, Inc. today announced that its scientists and executives will present at three upcoming scientific and medical conferences in March.

March 2, 2023
·
3 min read
Business

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023

Lineage Cell Therapeutics, Inc. today announced that it will report its fourth quarter and full year 2022 financial and operating results on Thursday, March 9, 2023, following the close of the U.S. financial markets.

March 2, 2023
·
2 min read
Business

Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials

Lantern Pharma Inc. today announced that it has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo M.D., M.Sc., MBA, as Vice President of Clinical Development, and several additional team members.

March 2, 2023
·
6 min read
Business

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

Wave Life Sciences Ltd. announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 22, 2023, to discuss the company’s fourth quarter and full year 2022 financial results and provide a business update.

March 2, 2023
·
1 min read
Biotech Bay

Biomea Fusion To Participate In Upcoming Investor Events

Biomea Fusion, Inc. today announced that Biomea’s management is scheduled to host investor meetings and participate in the following upcoming events.

March 2, 2023
·
3 min read